Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-01-22
2008-01-22
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S345000, C435S069100
Reexamination Certificate
active
10485454
ABSTRACT:
A vaccine against disease caused by papilloma viruses is described in certain embodiments, as well as certain vectors, obtainable by the following methods: (a) one or more expression vectors that contain the DNA code for a structural protein of papilloma viruses or a fragment thereof are injected into mammals, whereby in at least some of the expression vectors randomly generated heterologous sequences are inserted into the DNA code (b) serums are obtained from the mammals and these are tested for the presence of antibodies against particles of various papilloma virus types, and (c) using the serums tested, the structural protein gene clones are identified that code for a polyvalent vaccine, and (d) the vaccine is produced from them. Procedures for producing a vaccine is also described, together with its use for vaccination against diseases caused by papilloma viruses.
REFERENCES:
patent: 4551270 (1985-11-01), Danos et al.
patent: 199 25 199 (2000-12-01), None
patent: 100 59 631 (2002-07-01), None
patent: WO 00/35479 (2000-06-01), None
patent: WO 01/97840 (2001-12-01), None
Pastrana et al., “NHPV16 VLP Vaccine Induces Human Antibodies That Neutralize Divergent Variants of HPV16,”Virology, vol. 279, pp. 361-369 (2001).
Donnelly et al., “Protection against Papillomavirus with a Polynucleotide Vaccine,”Journal of Infectious Diseases, vol. 713, pp. 314-320 (1996).
Giroglou et al., “Immunological analyses of human papillomavirus capsids,”Vaccine, vol. 19, pp. 1783-1793 (2001).
Touze, et al., “The L1 Major Capsid Protein of Human Papillomavirus Type 16 Variants Affects Yield of Virus-Like Particles Produced in an Insect Cell Expression System,”J. Clin. Microbiol., vol. 36, No. 7, pp. 2046-2051 (Jul. 1998).
Kowalczyk et al., “Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16,”Vaccine, vol. 19, pp. 3583-3590 (2001).
Schreckenberger et al., “Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization,”Vaccine, vol. 19, pp. 227-233 (2001).
Sundaram et al., “Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge,”Vaccine, vol. 15, No. 6/7, pp. 664-671 (1997).
Leder et al., “Enhancement of Capsid Gene Expression: Preparing the Human Papillomavirus Type 16 Major Structural Gene L1 for DNA Vaccination Purposes,”J. Virol., vol. 75, No. 19, pp. 9201-9209 (Oct. 2001).
Beitburd et al., “Human papillomavirus vaccines,”Cancer Biology, vol. 9, pp. 431-445 (1999).
Roden et al., “Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing Epitopes,”Virology, vol. 270, pp. 254-257 (2000).
Slupetzky et al, Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops, Journal of General Virology, (2001), 2799-2804, 82, Printed in Great Britian.
Gissmann Lutz
Möller Martin
Pohlmeyer Kai
Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rech
Patterson Thuente Skaar & Christensen P.A.
Salimi Ali R.
LandOfFree
Polyvalent vaccine against diseases caused by papilloma... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyvalent vaccine against diseases caused by papilloma..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyvalent vaccine against diseases caused by papilloma... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3938217